Fiche publication
Date publication
août 2020
Journal
Cells
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DENAT Franck
Tous les auteurs :
Kalot G, Godard A, Busser B, Pliquett J, Broekgaarden M, Motto-Ros V, Wegner KD, Resch-Genger U, Köster U, Denat F, Coll JL, Bodio E, Goze C, Sancey L
Lien Pubmed
Résumé
Boron neutron capture therapy (BNCT) is a radiotherapeutic modality based on the nuclear capture of slow neutrons by stable B atoms followed by charged particle emission that inducing extensive damage on a very localized level (<10 μm). To be efficient, a sufficient amount of B should accumulate in the tumor area while being almost cleared from the normal surroundings. A water-soluble aza-boron-dipyrromethene dyes (BODIPY) fluorophore was reported to strongly accumulate in the tumor area with high and BNCT compatible Tumor/Healthy Tissue ratios. The clinically used B-BSH (sodium borocaptate) was coupled to the water-soluble aza-BODIPY platform for enhanced B-BSH tumor vectorization. We demonstrated a strong uptake of the compound in tumor cells and determined its biodistribution in mice-bearing tumors. A model of chorioallantoic membrane-bearing glioblastoma xenograft was developed to evidence the BNCT potential of such compound, by subjecting it to slow neutrons. We demonstrated the tumor accumulation of the compound in real-time using optical imaging and ex vivo using elemental imaging based on laser-induced breakdown spectroscopy. The tumor growth was significantly reduced as compared to BNCT with B-BSH. Altogether, the fluorescent aza-BODIPY/B-BSH compound is able to vectorize and image the B-BSH in the tumor area, increasing its theranostic potential for efficient approach of BNCT.
Mots clés
10B-BSH, BNCT, NIR-I, SWIR, aza-BODIPY, boron compound, in ovo model, optical imaging, theranostic
Référence
Cells. 2020 Aug 25;9(9):
